Therma Bright Inc. TBRIF
Set alert
0.03 USD 0.00 0.00%
At close · Oct 30
0.025 Day range 0.0255
0.022 52-week range 0.066
- YTD
- -10.71%
- 1 year
- -57.63%
- Open
- 0.0255
- Prev close
- 0.025
- Mkt cap
- 1.53M
- Vol
- 50.00K
- Avg vol
- 2.56K
- EPS
- -0.07
- P/E
- 0.00
More statistics
- Low
- 0.025
- High
- 0.0255
3M chart
Signals (19)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 29, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
News
- Therma Bright Announces up to $420,000 Non-Brokered Private Placement
- Therma Bright Inc. Completes Debt Settlements
- Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume
- Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
- Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
- Therma Bright Grants Stock Options
- Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
- Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
- Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
- Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Your note
Sign in to keep a note on TBRIF — it syncs with the Stock Master app.